Pharmaceuticals
Takeda chief says China’s drug development capabilities are approaching US standards
An Astellas Pharma office in Beijing. The company is preparing to open a new R&D facility in a Beijing industrial park. (Astellas Pharma)
TOKYO — Japanese pharmaceutical companies are increasing investment in China, the world’s second-largest market, as they seek to harness the country’s rapidly improving drug discovery capabilities and identify promising new treatment candidates.
Also Read
- The Jerusalem Post Launches Inaugural Asia-Pacific Summit in Sydney
- US Senior Advisor Proposes Unified Government Framework for Libya, FT Reports
- Japanese Authorities Investigate Major Ice Cream Manufacturers for Alleged Price-Fixing</TITLE]The investigation into suspected price-fixing cartels within the ice cream industry comes at a time when Japan is grappling with record-breaking summer temperatures.
- Emergency Response Saves Lives After Small Aircraft Crashes on Texas Highway